Tag Archives: Hepatitis

Study reveals viral hepatitis more deadly than HIV/AIDS in Europe

Hepatitis B

Tweet The Global Burden of Disease Study 2010 (GBD 2010) revealed on April 11 at the International Liver CongressTM 2014 that viral hepatitis is more deadly across European Union countries than HIV/AIDS. The study showed that in 2010, 10 times … Read More »

Filed in Medical Countermeasures | Tagged , | 1 Comment

Bristol-Myers Squibb announces new drug applications for hepatitis C treatments


TweetBristol-Myers Squibb announced on Monday that it submitted new drug applications with the United States Food and Drug Administration for daclatasvir and asunaprevir, which are used to treat 1b hepatitis C. “These FDA submissions represent a major step towards offering … Read More »

Filed in Medical Countermeasures | Tagged , | 1 Comment

Janssen initiates Phase 3 trials of combination dose of simeprevir and sofosbuvir

Janssen Pharmaceutical Companies

TweetJanssen R&D Ireland announced on Wednesday that it is recruiting approximately 400 patients for two Phase 3 trials of simeprevir and sofosbuvir, which treat chronic genotype 1 hepatitis C virus infection. “The combination of simeprevir and sofosbuvir with and without … Read More »

Filed in Medical Countermeasures | Tagged , | 1 Comment

HIV/hepatitis C patients 80 percent more likely to develop cirrhosis

hepatitis C

Tweet Researchers at the Perelman School of Medicine at the University of Pennsylvania recently conducted a study and found that patients with HIV/hepatitis C co-infections were 80 percent more likely to develop cirrhosis than hepatitis C-only patients. The study, which … Read More »

Filed in Medical Countermeasures | Tagged , , | Comments Off

Researchers discover gene variant protects against relapse of hepatitis C

hepatitis C

Tweet  Researchers at Sahlgrenska Academy at the University of Gothenburg said on Thursday that they have identified a gene that shows why some patients with hepatitis C do not relapse after receiving treatment More than 100 million people are infected … Read More »

Filed in Medical Countermeasures | Tagged , | Comments Off

Merck reveals HCV/HIV treatment Phase 2 trial results


TweetMerck announced on Wednesday the results of a Phase 2 clinical trial of its MK-5172/MK-8742 treatment for HIV/Hepatitis C co-infection. MK-5172/MK-8742 is an oral, once-daily regimen treatment against Hepatitis C infection for patients co-infected with HCV and HIV. The treatment … Read More »

Filed in Medical Countermeasures | Tagged , , | Comments Off

Rutgers team determines structure of hepatitis C surface protein

hepatitis C

Tweet Researchers at Rutgers University recently released study results that revealed the structure of a hepatitis C surface protein, which could assist in developing a vaccine. Joseph Marcotrigiano, an associate professor of chemistry and chemical biology and the study’s lead … Read More »

Filed in Medical Countermeasures | Tagged , | Comments Off

Study finds DNA coding can affect ability to fight Hepatitis C

hepatitis C

Tweet A recently study, led by Dr. Ram Savan of the University of Washington, revealed a person’s DNA coding of chromosome 19 can have an effect on that person’s ability to fight off Hepatitis C infection. Hepatitis C can lead … Read More »

Filed in Medical Countermeasures | Tagged , | Comments Off

Gilead submits NDA for hepatitis C treatment

FDA approves new, effective hepatitis C medication

New injection-free drug combination cures toughest cases of hepatitis C

Hepatitis C infection varies widely among U.S. Hispanics

Marketing validated for Bristol-Myers Squibb HCV treatment in EU

ND DOH reports investigation of Hepatitis C outbreak inconclusive

New HCV drug could cost $1,000 per pill

Boehringer Ingelheim’s hepatitis C antiviral shows promise in Phase III study

WHO confirms hepatitis E virus in Tanzania

EASL revises best practices for hepatitis C virus

Scripps scientists capture first ever detailed photo of HCV protein

Janssen Therapeutics receives approval for hepatitis C medication

Sinovac receives award to supply hepatitis A vaccine in Jiangsu province

Gilead announces Phase II results in hepatitis C trials

Treatment for chronic hepatitis C earns FDA advisory committee approval

ABL enters into contract with AEEH for development of HepatiC software

Inovio begins clinical trials on hepatitis C vaccine

Bristol-Myers Squibb launches partnership to cure chronic diseases

Addition of danoprevir to hepatitis C treatments shown to improve results

Maine CDC looks into HAV case at community event

NYC launches initiative to control hepatitis C prevalence in the city

Liver specialists urge hepatitis C screening strategy in Canada

New study shines light on fight against hepatitis C and hepatitis B

Medivir AB announces successful interim test results for HCV drug